{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Oncolytics Biotech Inc."},"Symbol":{"label":"Symbol","value":"ONCY"},"Address":{"label":"Address","value":"322 Ã¢Â¿Â¿ 11TH AVENUE SW,SUITE 804, CALGARY, Alberta, T2R-0C5, Canada"},"Phone":{"label":"Phone","value":"+1 403 670-7377"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Oncolytics Biotech Inc is a development-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. Its clinical development plan has the approval of its products as quickly as possible and expands its products into commercially valuable new treatment areas as objectives. The company's product pipeline includes Bavencio, Keytruda, Retifanlimab, and Tecentriq."},"CompanyUrl":{"label":"Company Url","value":"https://www.oncolyticsbiotech.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Amy Levin","title":"Vice President-Clinical Operations"},{"name":"Thomas C Heineman","title":"Chief Medical Officer"},{"name":"Wayne F. Pisano","title":"Chairman & Chief Executive Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}